Wnt Signaling in 4R-Tauopathies

Wnt Signaling in 4R-Tauopathies

Overview

The Wnt/β-catenin signaling pathway plays a critical role in neuronal development, synaptic plasticity, and cellular homeostasis. Dysregulation of this pathway has been implicated in multiple neurodegenerative diseases, including the 4R-tauopathies: Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17 (MAPT mutations). This analysis compares how Wnt signaling, and related pathways including GSK3β, YAP/TAZ, and the Hippo pathway, differ across these diseases.

Wnt/β-Catenin Signaling Pathway

Canonical Wnt Pathway

The canonical Wnt/β-catenin pathway is initiated by Wnt ligand binding to Frizzled receptors and LRP5/6 co-receptors. This prevents β-catenin degradation, allowing it to accumulate and translocate to the nucleus where it interacts with TCF/LEF transcription factors to regulate target genes[@clevers2012].

In 4R-tauopathies, Wnt/β-catenin signaling shows disease-specific alterations:

| Disease | Wnt Pathway Activity | Key Findings |
|---------|-----------------|-------------|
| PSP | Reduced | Decreased nuclear β-catenin in basal ganglia[@marchetti2020] |
| CBD | Reduced | Wnt ligand downregulation in motor cortex |
| AGD | Variable | Region-specific changes in entorhinal cortex |
| GGT | Reduced | Oligodendrocyte lineage affected |
| FTDP-17 | Variable | Mutation-dependent effects |

Non-Canonical Wnt Pathways

Wnt Signaling in 4R-Tauopathies

Overview

The Wnt/β-catenin signaling pathway plays a critical role in neuronal development, synaptic plasticity, and cellular homeostasis. Dysregulation of this pathway has been implicated in multiple neurodegenerative diseases, including the 4R-tauopathies: Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17 (MAPT mutations). This analysis compares how Wnt signaling, and related pathways including GSK3β, YAP/TAZ, and the Hippo pathway, differ across these diseases.

Wnt/β-Catenin Signaling Pathway

Canonical Wnt Pathway

The canonical Wnt/β-catenin pathway is initiated by Wnt ligand binding to Frizzled receptors and LRP5/6 co-receptors. This prevents β-catenin degradation, allowing it to accumulate and translocate to the nucleus where it interacts with TCF/LEF transcription factors to regulate target genes[@clevers2012].

In 4R-tauopathies, Wnt/β-catenin signaling shows disease-specific alterations:

| Disease | Wnt Pathway Activity | Key Findings |
|---------|-----------------|-------------|
| PSP | Reduced | Decreased nuclear β-catenin in basal ganglia[@marchetti2020] |
| CBD | Reduced | Wnt ligand downregulation in motor cortex |
| AGD | Variable | Region-specific changes in entorhinal cortex |
| GGT | Reduced | Oligodendrocyte lineage affected |
| FTDP-17 | Variable | Mutation-dependent effects |

Non-Canonical Wnt Pathways

The non-canonical Wnt pathways include Wnt/PCP (planar cell polarity) and Wnt/Ca²⁺ signaling. These pathways are particularly relevant to neuronal polarity, migration, and axonal guidance. In 4R-tauopathies, non-canonical Wnt dysregulation contributes to the selective vulnerability of specific neuronal populations.

GSK3β: The Convergence Point

GSK3β Biology

Glycogen synthase kinase 3β (GSK3β) is a serine/threonine kinase that plays multiple roles in neuronal function:

• Tau phosphorylation: GSK3β is one of the primary kinases that phosphorylates tau at disease-relevant sites (Thr181, Ser199, Ser202, Thr205, Ser396, Ser404)
• β-catenin regulation: GSK3β phosphorylates β-catenin, targeting it for degradation
• Synaptic plasticity: GSK3β regulates NMDA receptor trafficking and synaptic function
• Gene transcription: Through β-catenin, GSK3β affects Wnt target gene expression

GSK3β in 4R-Tauopathies

GSK3β activity is altered in multiple 4R-tauopathies:

PSP

GSK3β activity is elevated in PSP brains, particularly in affected regions including the substantia nigra and globus pallidus. This hyperactivity contributes to:

• Increased tau phosphorylation at GSK3β-preferred sites
• Reduced β-catenin signaling
• Impaired synaptic function
• Neuroinflammation amplification

CBD

GSK3β shows region-specific activation in CBD motor cortex and basal ganglia. The pattern differs from PSP, with more pronounced activation in cortical regions. This may reflect the distinct neuroanatomical vulnerability patterns.

AGD

GSK3β activation in AGD is more restricted to temporal lobe structures, particularly the entorhinal cortex and amygdala. This correlates with the distribution of argyrophilic grains.

GGT

In GGT, GSK3β dysregulation affects both neurons and oligodendrocytes. The oligodendrocyte involvement is unique among 4R-tauopathies and may relate to the glial fibrillary pathology.

FTDP-17

GSK3β alterations in FTDP-17 depend on the specific MAPT mutation:

• Exon 10 splicing mutations (N279K, P301L, +10, +12, +14, +16): Lead to increased 4R tau, substrate overload
• Missense mutations (R406W, V337M): Affect phosphorylation and aggregation properties differently

GSK3β as Therapeutic Target

Multiple therapeutic approaches target GSK3β:

| Agent | Mechanism | Development Stage |
|-------|----------|---------------|
| Tideglusib | GSK3β inhibitor | Phase 2 (failed) |
| Lithium | GSK3β inhibitor | Repurposed |
| AR-AA411 | Selective inhibitor | Preclinical |
| Peptide inhibitors | Substrate-specific | Research |

The failure of Tideglusib in clinical trials highlights the complexity of GSK3β inhibition, as complete inhibition disrupts normal neuronal function.

YAP/TAZ Signaling

YAP/TAZ Biology

Yes-associated protein (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ) are the two downstream effectors of the Hippo pathway. They regulate gene expression by interacting with TEAD transcription factors and other partners[@goodridge2018].

Key functions in the nervous system:

• Neural stem cell proliferation: YAP/TAZ maintain neural progenitor pools
• Neuronal differentiation: Required for proper neuronal maturation
• Synaptic formation: Regulates synapse development
• Cell survival: Anti-apoptotic functions
• Mechanotransduction: Responds to mechanical signals

YAP/TAZ in 4R-Tauopathies

PSP

YAP/TAZ localization is altered in PSP brainstem nuclei. Nuclear YAP/TAZ decreases in affected neurons, correlating with tau pathology. This reduction may contribute to:

• Impaired cellular homeostasis
• Reduced stress responses
• Decreased neuroprotection

CBD

In CBD, YAP/TAZ alterations are most pronounced in motor and premotor cortices. The pattern differs from PSP, with more prominent cytosolic retention. This may relate to the cortical involvement characteristic of CBD.

AGD

YAP/TAZ changes in AGD are relatively subtle compared to other 4R-tauopathies, reflecting the more limited regional involvement.

GGT

YAP/TAZ signaling shows distinct dysregulation in GGT oligodendrocytes. The glial fibrillary tau pathology affects YAP/TAZ cellular distribution differently than in neuronal tauopathies.

FTDP-17

YAP/TAZ alterations in FTDP-17 depend on the specific mutation and brain region. Some MAPT mutations directly or indirectly affect YAP/TAZ nuclear signaling.

Hippo Pathway

Hippo Pathway Biology

The Hippo pathway regulates organ size through a kinase cascade:

• MST1/2 (Hippo) → LATS1/2 → YAP/TAZ phosphorylation

Hippo in 4R-Tauopathies

| Disease | Hippo Pathway Activity | Neuronal Effects |
|---------|------------------|---------------|
| PSP | Increased (MST1/2 active) | YAP/TAZ exclusion from nucleus |
| CBD | Moderately Increased | Variable by region |
| AGD | Variable | Region-dependent |
| GGT | Altered in glia | Glial dysfunction |
| FTDP-17 | Mutation-dependent | Variable |

Cross-Disease Comparison

Molecular Integration

The Wnt/β-catenin, GSK3β, YAP/TAZ, and Hippo pathways form an integrated network:

Disease-Specific Patterns

| Pathway Component | PSP | CBD | AGD | GGT | FTDP-17 |
|----------------|-----|-----|-----|-----|----------|
| Wnt/β-catenin | ↓↓ | ↓↓ | ↓ | ↓↓ | variable |
| GSK3β activity | ↑↑ | ↑ | ↑ | ↑ | mutation-dependent |
| YAP/TAZ (nuclear) | ↓↓ | ↓ | ↓ | ↓ (glia) | variable |
| Hippo pathway | ↑↑ | ↑ | - | ↑ (glia) | - |
| Tau pathology | 4R > 3R | 4R > 3R | 4R | 4R (glia) | 4R |

Therapeutic Implications

Common Targets

Several therapeutic strategies could benefit multiple 4R-tauopathies:

| Target | Strategy | Pipeline |
|--------|---------|---------|
| GSK3β | Partial inhibition | Preclinical/Phase 2 |
| Wnt pathway activation | Small molecule agonists | Research |
| YAP/TAZ restoration | Activity modulators | Research |
| Tau clearance | Immunotherapies | Phase 2-3 |

Disease-Specific Approaches

• PSP: Focus on brainstem-penetrant GSK3β inhibitors, brainstem-targeting Wnt modulators
• CBD: Cortically-penetrant approaches, motor cortex YAP/TAZ targeting
• AGD: Region-specific temporal lobe interventions
• GGT: Glial-targeting therapies, oligodendrocyte protection
• FTDP-17: Mutation-specific ASO approaches

Summary and Conclusions

The cross-disease comparison reveals both shared mechanisms and disease-specific alterations in Wnt signaling and related pathways:

Understanding the specific pattern of pathway dysregulation in each 4R-tauopathy enables more precise therapeutic targeting.

See Also

• [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [GSK3β Signaling](/mechanisms/gsk3-beta-signaling)
• [Wnt Signaling in Neurodegeneration](/mechanisms/wnt-signaling-neurodegeneration)
• [YAP/TAZ Signaling in Neurodegeneration](/mechanisms/yap-taz-hippo-signaling-neurodegeneration)
• [Hippo Pathway in Neurodegeneration](/mechanisms/hippo-pathway-neurodegeneration)
• [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway)
• [PSP](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease)
• [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy)
• [FTDP-17](/diseases/ftdp-17)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Wnt Signaling in 4R-Tauopathies discovered through SciDEX knowledge graph analysis: